Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com
APR 26, 2012 - 18:52 ET
CEO Discusses Company Pipeline and Connections With Dana-Farber, Pfizer and Beth Israel Deaconess Medical Center
DALLAS, TX--(Marketwire - April 26, 2012) - TheStreetBeat.com is pleased to announce the latest installment of its CEO Interview Series. A two-part interview will begin airing today featuring a question and answer session with Cellceutix Corporation (
In the interview, Mr. Ehrlich speaks with The Street Beat reporter Bolton Flautt about ongoing activities at Cellceutix with the three of its drugs that are actively being developed as indications for cancer, psoriasis and autism. In Part One, Mr. Ehrlich provides commentary on the upcoming clinical trials for Kevetrin™ to be held at Harvard's Dana-Farber, the combinations studies with two Pfizer drugs that are going to be conducted at Beth Israel Deaconess Medical Center and the possibilities involved with each. In Part Two of the interview, which will be released tomorrow, Friday, April 27th, the conversation turns towards the status of Prurisol™ for psoriasis and KM-391 for the core symptoms of autism.
Interested parties looking to learn more about this exciting biotech are encouraged to listen to the interview at:
The Street Beat is a new digital financial media company, focusing on small-cap companies and the penny stock markets. By leveraging today's technology to continuously grow its network of over 1400 financially centric newspaper, television, and radio websites, The Street Beat has quickly become one of the top sources for investors seeking information on today's emerging companies. Through an array of digital and marketing services, The Street Beat offers users and subscribers daily innovative business news, real-time market commentary, investment tools, market education, as well as stories, articles, videos, and market briefs from a full staff of experienced and dedicated journalists. Visit us today at www.TheStreetBeat.com.